drugset

drugset / Trial / NCT00560963

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

NCT00560963 ↗

Phase 1/2 Completed 21 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

A dose finding study in locally advanced and/or metastatic pancreatic cancer patients

Timeline

Start: 2007-10
Primary completion: 2011-01
Completion: 2011-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	—	—

Indications